Cowen Remains Positive as Pfizer (PFE) Reports a 3Q Beat and raise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pre-Open Stock Movers 10/27: (TRIV) (UQM) (BABA) Higher; (RRTS) (RCII) (MRVL) Lower (more...)
October 27, 2015 9:31 AM EDTTriVascular Technologies, Inc. (Nasdaq: TRIV) 50.8% HIGHER; Endologix (NASDAQ: ELGX) and TriVascular Technologies, Inc. (Nasdaq: TRIV) announced today that they have entered into a definitive merger agreement under which Endologix and TriVascular will combine in a stock and cash transaction. The transaction is valued at $9.10 per TriVascular share, or a total of approximately $211 million, based on Endologix's closing stock price of $13.81 per share on October 23, 2015.
Roadrunner Transportation (NYSE:... More
Top U.S. drugmakers ride new products to strong results
October 27, 2015 6:53 AM EDT(In Oct 27 story, paragraph 9 corrects number of Ibrance patients to 15,000 from 50,000)
By Bill Berkrot and Ransdell Pierson
NEW YORK (Reuters) - Growing sales of expensive new cancer drugs and other newer medicines propelled top U.S. drugmakers Pfizer Inc (NYSE: PFE), Merck & Co (NYSE: MRK) and Bristol-Myers Squibb Co (NYSE: BMY) to stronger-than-expected third-quarter profits.
The results, announced on Tuesday, demonstrate that the "patent cliff" that had been hurting earnings as huge-selling drugs like Pfizer's Lipitor and Bristol's Plavix went generic is now... More
Pfizer (PFE) Tops Q3 EPS by 9c
October 27, 2015 6:46 AM EDTPfizer (NYSE: PFE) reported Q3 EPS of $0.60, $0.09 better than the analyst estimate of $0.51. Revenue for the quarter came in at $12.1 billion versus the consensus estimate of $11.56 billion.
EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, Our business continues to demonstrate strength across key product lines and geographies which has resulted in another quarter of strong financial performance. We have been intently focused on seeking to generate a greater portion of our earnings from increased revenues and I see our product portfolio, product pipeline and recent business development activity as... More
Trading Radar for 10/26: Apple (AAPL), Twitter (TWTR), Alibaba (BABA), Comcast (CMCSA), Pfizer (PFE) Report
October 26, 2015 2:16 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
9:00am EDT
Case-Shiller 20-City Index - Street sees 5.0%Earnings:
AIXTRON SE (Nasdaq: AIXG) - consensus loss $0.08
AK Steel (NYSE: AKS) - consensus loss $0.23
AVX Corp. (NYSE: AVX) - consensus EPS $0.20
Active Power (Nasdaq: ACPW) - consensus loss $0.02... More
